

# Miloš D Miljković

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/406106/publications.pdf>

Version: 2024-02-01

39  
papers

998  
citations

687363

13  
h-index

454955

30  
g-index

39  
all docs

39  
docs citations

39  
times ranked

1581  
citing authors

#	ARTICLE	IF	CITATIONS
1	Triple combination of BET plus PI3K and NF-�B inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma. <i>Blood Advances</i> , 2022, 6, 2346-2360.	5.2	6
2	Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry. <i>Blood Reviews</i> , 2021, 47, 100778.	5.7	8
3	Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia. <i>Translational Oncology</i> , 2021, 14, 100913.	3.7	4
4	Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018. <i>JAMA Internal Medicine</i> , 2021, 181, 162.	5.1	27
5	Targeted based therapy in nodal T-cell lymphomas. <i>Leukemia</i> , 2021, 35, 956-967.	7.2	5
6	NF-�B-induced R-loop accumulation and DNA damage select for nucleotide excision repair deficiencies in adult T cell leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	17
7	T-cell lymphomas: A 5-body problem. <i>Seminars in Hematology</i> , 2021, 58, 67-69.	3.4	0
8	Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies. , 2021, 9, e002193.		27
9	Next-Generation Sequencing-Based Monitoring of Circulating Tumor DNA Reveals Clonotypic Heterogeneity in Untreated PTCL. <i>Blood Advances</i> , 2021, 5, 4198-4210.	5.2	8
10	Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 441-448.	1.5	16
11	Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2020, 96, 106420.	0.8	3
12	Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	77
13	IL-15 in the Combination Immunotherapy of Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 868.	4.8	119
14	Postnatal development of metallophilic macrophages in the rat thymus. <i>Journal of Veterinary Medicine Series C: Anatomia Histologia Embryologia</i> , 2020, 49, 433-439.	0.7	2
15	<sup>90</sup>Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 249-261.	1.0	9
16	Phase 1b/2 Study of Vopor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis. <i>Blood</i> , 2020, 136, 44-45.	1.4	13
17	Phase 1 Study of Subcutaneous Recombinant Human (rh) Interleukin-15 and Intravenous Alemtuzumab in Patients with Rrelapsed/Refractory T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 23-24.	1.4	2
18	Cytokines in the Treatment of Cancer. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 6-21.	1.2	315

#	ARTICLE	IF	CITATIONS
19	Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. <i>Blood</i> , 2019, 134, 1406-1414.	1.4	80
20	Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3320-3323.	1.3	3
21	Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations. <i>Haematologica</i> , 2019, 104, e227-e227.	3.5	1
22	IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. <i>Clinical Cancer Research</i> , 2019, 25, 4945-4954.	7.0	82
23	Interactions between direct anticoagulants and chemotherapy. <i>Annals of Oncology</i> , 2019, 30, 1170.	1.2	1
24	Anticoagulation for atrial fibrillation in patients with active cancer. <i>International Journal of Cardiology</i> , 2019, 280, 98.	1.7	1
25	Atrial Fibrillation and Stroke Risk in Patients With Cancer: A Primer for Oncologists. <i>Journal of Oncology Practice</i> , 2019, 15, 641-650.	2.5	25
26	Phase 1b Study of Viper (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis. <i>Blood</i> , 2019, 134, 2867-2867.	1.4	4
27	Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies. <i>Blood</i> , 2019, 134, 1558-1558.	1.4	2
28	Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3052-3052.	1.4	0
29	End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. <i>Haematologica</i> , 2018, 103, 1337-1344.	3.5	63
30	Abstract 313: Tbeta induces G2/M cell cycle arrest and sensitizes osteosarcoma cells to etoposide in a p53-independent manner. , 2017, , .		0
31	Patterns of Radiation-Associated Lymphopenia in Children with Cancer. <i>Cancer Investigation</i> , 2016, 34, 32-38.	1.3	6
32	Description and pilot evaluation of the Metabolic Irregularities Narrowing down Device software: a case analysis of physician programming. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2015, 5, 25793.	0.8	1
33	“Allow Natural Death” versus “Do Not Resuscitate”: What Do Patients with Advanced Cancer Choose?. <i>Journal of Palliative Medicine</i> , 2015, 18, 457-460.	1.1	16
34	From the Euthanasia Society to Physician Orders for Life-Sustaining Treatment. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 438-443.	2.0	6
35	Are “Allow Natural Death” orders preferable to “Do Not Resuscitate” orders for patients with advanced cancer?. <i>Journal of Clinical Oncology</i> , 2013, 31, e20685-e20685.	1.6	0
36	Novel Medical Therapies of Recurrent and Metastatic Gastroenteropancreatic Neuroendocrine Tumors. <i>Digestive Diseases and Sciences</i> , 2012, 57, 9-18.	2.3	22

#	ARTICLE	IF	CITATIONS
37	Role of CCL19/21 and its possible signaling through CXCR3 in development of metallophilic macrophages in the mouse thymus. <i>Histochemistry and Cell Biology</i> , 2011, 135, 593-601.	1.7	4
38	Morphometric study of healthy jejunal and ileal mucosa in adult and aged subjects. <i>Histology and Histopathology</i> , 2010, 25, 153-8.	0.7	17
39	Metallophilic macrophages are fully developed in the thymus of autoimmune regulator (Aire)-deficient mice. <i>Histochemistry and Cell Biology</i> , 2009, 131, 643-649.	1.7	6